Serum Citrate in Diagnosis and Follow-up for Glaucoma

January 7, 2015 updated by: University Hospital, Basel, Switzerland
Glaucoma might be a mitochondria associated disease. Since citrate is a major component in mitochondrial metabolism its determination in blood might serve as a biomarker.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

20

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Switzerland
    • Basel-Stadt
      • Basel, Basel-Stadt, Switzerland, 4031
        • University Hospital Basel

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

tertiary university center

Description

Inclusion Criteria:

  • age> 18 years
  • glaucoma

Exclusion Criteria:

  • Active ocular inflammation
  • Ocular Hypertension
  • Nephropathy
  • Alcohol-, Drug abuse
  • Mitochondriopathy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
1
glaucoma patients
Procedure: drawing blood sample
fasting blood sample
2
non-glaucoma controls
Procedure: drawing blood sample
fasting blood sample

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
serum citrate level
Time Frame: 1
1

Secondary Outcome Measures

Outcome Measure
Time Frame
urine citrate
Time Frame: 1
1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Hospital, Basel, Switzerland

Collaborators

Kantonsspital Baselland Bruderholz

Investigators

  • Principal Investigator: David Goldblum, MD, University Hospital, Basel, Switzerland
  • Study Chair: Josef Flammer, MD, University Hospital, Basel, Switzerland
  • Study Director: Selim Orguel, MD, University Hospital, Basel, Switzerland
  • Principal Investigator: Stephan Fraenkl, MD, University Hospital, Basel, Switzerland
  • Principal Investigator: Fabrizio Branca, MD, University Basel

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2008

Primary Completion (Actual)

December 1, 2012

Study Completion (Actual)

July 1, 2013

Study Registration Dates

First Submitted

December 5, 2008

First Submitted That Met QC Criteria

December 5, 2008

First Posted (Estimate)

December 8, 2008

Study Record Updates

Last Update Posted (Estimate)

January 8, 2015

Last Update Submitted That Met QC Criteria

January 7, 2015

Last Verified

January 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • EK 325/08

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe